Status:
COMPLETED
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
Lead Sponsor:
Amgen
Conditions:
Migraine
Eligibility:
All Genders
18-99 years
Phase:
PHASE4
Brief Summary
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Participant has provided informed consent
- History of migraine (with or without aura) for ≥ 12 months before screening
- ≥ 4 migraine days per month on average across the 3 months prior to screening
- Treatment with 1 oral migraine preventive medication and/or concomitant use of OnabotulinumtoxinA injections for migraine prevention.
- Participant reports to their provider intolerance or insufficient response with their current preventative treatment
Exclusion
- History of cluster headache or hemiplegic migraine headache
- Unable to differentiate migraine from other headaches
- Evidence of substance-related disorders
- Active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)
- No therapeutic response with \> 3 migraine preventive medication categories
- Used a prohibited medication, device, or procedure
- Other clinically significant disorder, condition, or disease
Key Trial Info
Start Date :
June 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 28 2023
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT04825678
Start Date
June 11 2021
End Date
September 28 2023
Last Update
September 19 2024
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Rehabilitation and Neurological Services LLC
Huntsville, Alabama, United States, 35805
2
Elite Clinical Studies LLC
Phoenix, Arizona, United States, 85018
3
Neurology Center of North Orange County
Fullerton, California, United States, 92835
4
The Neurology Group
Pomona, California, United States, 91767